| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Review |
| Article Title |
Liver transplantation for combined hepatocellular-cholangiocarcinoma: Current evidence, selection criteria, and therapeutic controversies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Rui-Quan Zhou, Pei-Jun Yang, Tian-Tong Liu, Dong-Dong Han, Xiao-Lei Liu, Li-Guo Liu, Shuang Si, Shi-Wei Yang, Shuai-Shuai Xu, Yi-Wen Guo and Hai-Dong Tan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| High-level Research Projects of China-Japan Friendship Hospital |
2022-NHLHCRF-LX-03-0301, 2023-NHLHCRF-LXYZ-01 |
|
| Corresponding Author |
Hai-Dong Tan, Chief Physician, MD, Second Department of Hepatopancreatobiliary Surgery, China-Japan Friendship Hospital, No. 2 Yinghua Dongjie, Hepingli, Beijing 100029, China. hpblt_cjfh@126.com |
| Key Words |
Combined hepatocellular-cholangiocarcinoma; Liver transplantation; Liver resection; Milan criteria; Lymphadenectomy; Vascular resection; Locoregional therapy; Systemic treatment |
| Core Tip |
Combined hepatocellular cholangiocarcinoma is a rare and aggressive liver malignancy with diagnostic and therapeutic challenges. Although surgical resection remains the primary curative approach, liver transplantation is emerging as a potential option for carefully selected patients, particularly those with early-stage tumors or cirrhosis. Adherence to stringent selection criteria, such as the Milan criteria, is crucial for optimizing post-transplant outcomes. Ongoing research aims to refine the selection framework and improve prognostic accuracy. |
| Publish Date |
2025-05-23 08:06 |
| Citation |
<p>Zhou RQ, Yang PJ, Liu TT, Han DD, Liu XL, Liu LG, Si S, Yang SW, Xu SS, Guo YW, Tan HD. Liver transplantation for combined hepatocellular-cholangiocarcinoma: Current evidence, selection criteria, and therapeutic controversies. <i>World J Gastrointest Surg</i> 2025; 17(5): 105783</p> |
| URL |
https://www.wjgnet.com/1948-9366/full/v17/i5/105783.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v17.i5.105783 |
